Why these categories are not interchangeable, and why evidence and FDA status should guide treatment decisions.
Many GLP-1 and related incretin medications are peptide-based drugs, but in clinical practice the phrase “peptide therapy” is often used for a much broader group of substances. That distinction matters. FDA-approved GLP-1 or dual-incretin medications have undergone formal review for specific indications, while many compounds marketed as wellness or recovery peptides have not.
| Topic | GLP-1 / incretin medications | Other marketed peptides |
|---|---|---|
| Clinical evidence | Large randomized trials exist for approved medications and indications. | Varies widely; some have limited or no high-quality human efficacy data for promoted uses. |
| Regulatory status | Some products are FDA-approved for obesity, diabetes or related indications. | Status varies by compound; many are unapproved or investigational. |
| Use in weight management | Can be evidence-based when prescribed for an appropriate indication. | Should not be assumed effective for weight loss simply because a compound is a peptide. |
| Medical monitoring | Requires individualized screening and follow-up. | Also requires careful evaluation of evidence, safety, source and regulatory status. |
Patients primarily seeking weight reduction should start with evidence-based obesity evaluation rather than selecting a substance based on marketing claims. Our Medical Weight Loss Los Angeles program evaluates health history, medications, body composition, sleep, nutrition and relevant medical conditions. Learn more about Semaglutide, Tirzepatide, and our GLP-1 weight-loss guide.
Patients may still ask about compounds associated with body composition, recovery or hormone signaling. Those questions deserve an evidence-based discussion. Review the Peptide Therapy Los Angeles hub, our evidence and regulatory guide, and the peptide safety and side-effects guide.
FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before marketing. Compounding can serve important medical needs in selected patients, but it should not be confused with FDA approval. FDA: Compounding and the FDA.
The comprehensive initial physician evaluation is $450 and is designed to establish care, review history and goals, identify relevant medical contributors, and determine whether diagnostic testing or treatment is clinically appropriate. Follow-up physician visits are $250.
Board Certified in Internal Medicine. Educational content only; individualized treatment depends on medical evaluation. Photo: National Cancer Institute / Unsplash.
